Latest news with #regenerativemedicine
Associated Press
4 days ago
- Business
- Associated Press
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
BORDEAUX, France--(BUSINESS WIRE)--May 27, 2025-- TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. This press release features multimedia. View the full release here: Vice-President Ambroise Fayolle, EIB and Frederic Desdouits, CEO TreeFrog Therapeutics sign financing of €30million to accelerate cell therapy programs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: 'Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector'. Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: 'We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas.' TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on CONTACT: Press contacts EIB Andrea Morawski,[email protected], mobile: +352 691 284 349 Website: Press Office:[email protected] TreeFrog Therapeutics Rachel Mooney Chief Communications Officer [email protected] Tel: +33 674063461 KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE INDUSTRY KEYWORD: OTHER HEALTH RESEARCH BANKING GENERAL HEALTH PROFESSIONAL SERVICES PUBLIC RELATIONS/INVESTOR RELATIONS SCIENCE BIOTECHNOLOGY COMMUNICATIONS FINANCE OTHER SCIENCE HEALTH SOURCE: TreeFrog Therapeutics Copyright Business Wire 2025. PUB: 05/27/2025 07:15 AM/DISC: 05/27/2025 07:14 AM
Arabian Business
5 days ago
- Business
- Arabian Business
Price of youth: Dubai's AEON Clinic leads push for biological age reversal with DNA targeted treatments
Biological age reversal, once relegated to the realm of science fiction, is fast becoming a clinical reality. Dubai's AEON Clinic offers several highly advanced treatments to clientele looking to achieve longevity, propelled by the vision of Founder and CEO Dr. Jaffer Khan. A veteran reconstructive and aesthetic surgeon in the UAE, Khan is placing a bold bet on the future of healthcare: reversing biological age through precision and regenerative medicine. From his clinic at Atlantis The Royal in Dubai, Khan is leading AEON Clinic, a high-end medical facility focused on extending healthspan rather than simply treating illness. The clinic targets a wealthy, globally mobile clientele with the promise of data-driven, preventive care that leverages cutting-edge science – from stem cell therapies to genomic sequencing. 'We're reversing biological age by looking at parameters such as DNA methylation,' said Khan in an exclusive interview with Arabian Business. 'There's an objective parameter that is changing. Your age is moving backwards biologically, not chronologically.' Although the price point remains high today, Khan is confident that as the technology scales and becomes more widely adopted, age-reversal treatments will move beyond the domain of the wealthy and become accessible to a broader population. Khan stresses that the approach at AEON Clinic is grounded in rigorous science rather than hype. 'We're not promising anything, you know. I mean, people come and they spend whatever $50,000 on a stem cell treatment, they are doing it knowing that we're not saying that this is going to be a game changer, a life changer for you.' The clinic provides patients with detailed diagnostics and clear benchmarks: 'Here is the science. Here is your current parameter. This is where we believe we can take you, and the rest is your journey,' he said. Data protection remains a pivotal challenge as healthcare moves deeper into personalised medicine. Khan believes that there can be excessive caution at times. 'I don't care if somebody knows my blood type. How is it going to change my life?' However, he calls for balanced regulation, 'HIPAA compliance has to happen. Okay? It has to be HIPAA compliant. You have to protect that data.' The ethical landscape surrounding regenerative medicine is complex, particularly concerning stem cell therapies. Khan pointed out the significant issues tied to embryonic stem cells. 'From an ethical perspective, regenerative medicine is right up there from stem cell technology, embryonic like, for example, one type of stem cells embryonic, but you have to kill the embryo to get it. So there's a huge ethical issue with that.' Yet the promise of such science is enormous. Breakthroughs in genetic engineering offer tantalising glimpses of the future. Khan highlighted experiments in animals demonstrating profound regenerative effects. 'Already in mice experiments, they are reversing age, growing their hair back. Blind mice are seeing again… You know all of these, what we call gene splicing, or gene transcription. It's there.' Technologies like CRISPR, which allow for precise editing of genetic sequences, have opened new frontiers. 'Since 2012 we can remove a bad segment of genomics and add a segment in what it costs for something like cystic fibrosis, maybe $2 million at the moment, but it won't be in 10 years' time,' Khan said. The dramatic drop in the cost of genome sequencing exemplifies how quickly the field is evolving. 'You know, it costs a billion dollars to decide for 3 billion to decipher the whole human genome. We do that now for $1,000 you know, as a test.' With technology advancing rapidly, treatments now available only to a wealthy few are expected to become broadly accessible. 'Although these treatments currently come with a considerably high price tag, Khan believes that in a few years when these technologies become more accessible and widespread – the service will not only be for the wealthy.' A critical part of AEON Clinic's philosophy is the long-term relationship it builds with patients. 'We're not just another retreat or one-off center. This is an ongoing clinical relationship based on diagnostics, biomarkers, and long-term planning,' Khan explained. Despite the promise of regenerative and precision medicine, Khan is clear-eyed about the importance of managing expectations. 'From an ethical point of view, we need to make sure that we introduce things without over delivering too many promises.' The clinic's approach is rooted in prudence: 'We should under promise and over deliver, rather than the other way around.' As longevity science advances, AEON Clinic is positioning itself to be a regional leader in a field that may redefine the future of healthcare. But Khan cautioned that the journey is just beginning and the technology still has to mature: 'This technology will be more and more available.' For now, patients willing to invest significant sums are embarking on what Khan calls a personal journey – one supported by cutting-edge diagnostics and treatments. 'We're reversing biological age… but what are the promises? We're not promising anything… This is where we believe we can take you, and the rest is your journey,' he concluded.
Yahoo
23-05-2025
- Business
- Yahoo
Regenerative Medicine Strategic Market Intelligence Report 2025: From Rare to Common - The Expanding Horizon of Gene Therapies
Explore the transformative potential of regenerative medicine in healthcare, focusing on curing diseases, eliminating cancer, and restoring tissues through innovative gene and cell therapies. Discover key industry leaders, emerging trends, and applications across therapeutic areas. Unlock insights into reshaping medical devices. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Regenerative Medicine (2025)" has been added to offering. The report offers insights into the fundamentals of regenerative medicine and its potential impact on the medical device industry. It highlights key innovators and emerging challengers in the field and provides an analysis of trends shaping the future of regenerative medicine. Regenerative medicine stands at the forefront of groundbreaking innovation in healthcare, revolutionizing the approach to curing diseases, eradicating cancer, and revitalizing damaged or aging tissues. Through advanced techniques in gene therapy, cell therapy, and tissue repair, this field aims to restore biological functions by correcting genetic defects, rebalancing cellular environments, and replacing compromised tissues. Core to this medical revolution is its capacity to reshape the landscape of the medical devices industry. By providing novel solutions and therapeutic strategies, regenerative medicine enhances patient care and outcomes, underscoring its vital role in the future of medicine. The integration of regenerative therapies not only addresses immediate medical challenges but also promises long-term healthcare stability by reducing the burden of chronic diseases and improving quality of life for patients worldwide. Regenerative medicine leaders are pioneering efforts to bring these therapies to clinical practice, concentrating on strategic expansions into more prevalent disease areas. Stakeholders investing in this dynamic theme anticipate a profound impact on healthcare delivery, setting new standards for therapeutic efficacy and patient well-being. As the field of regenerative medicine continues to evolve, it holds the promise of unprecedented advancements, fostering a healthcare environment where diseases are not merely treated but cured, and where age-related degenerations are effectively reversed or mitigated. In conclusion, the growth of regenerative medicine is a key driver of transformation within the medical industry, offering opportunities that extend far beyond current healthcare capabilities. Engage with this innovative field to remain at the cutting edge of medical technology and patient care solutions. Scope of Regenerative Medicine Regenerative medicine offers transformative potential across healthcare sectors. Its diverse applications extend into various therapeutic areas. Gene therapies primarily target rare diseases, with future progression into common and polygenic conditions. Key Topics Covered: Executive Summary Players Technology Briefing Trends Industry Analysis Value Chain Companies Sector Scorecard Glossary Further Reading Thematic Research Methodology About the Analyst Contact the Publisher For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Associated Press
22-05-2025
- Health
- Associated Press
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the formation of its Clinical Advisory Board. The board will consist of five members and will be chaired by Dr. Robert Gabbay. This globally respected group of experts will provide critical guidance as the company advances clinical development of its Cell Pouch Bio-hybrid Organ with islet cells in patients with T1D. The Sernova clinical advisory board members include: Robert Gabbay, MD, PhD, FACP – Clinical Advisory Board Chair Associate Professor at Harvard Medical School and the Joslin Diabetes Center Dr. Gabbay formerly served as Chief Scientific and Medical Officer of the American Diabetes Association (ADA) and Chief Medical Officer of the Joslin Diabetes Center. His research focuses on innovative models of diabetes care to enhance diabetes outcomes and improve the lives of people with diabetes. Dr. Gabbay has received funding from the National Institute of Health Diabetes, Digestive and Kidneys Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and the Center for Medicare and Medicaid Innovation for his care transformation work. Mark Atkinson, PhD Director, University of Florida Diabetes Institute; Professor, Departments of Pathology and Pediatrics Dr. Atkinson is one of the world's most cited scientists in type 1 diabetes research and serves as the American Diabetes Association Eminent Scholar at the University of Florida. With over 750 scientific publications and more than 40 years of research experience, he has played a leading role in efforts to understand the pathogenesis, prevention, and treatment of T1D. Dr. Atkinson is the founding executive director of nPOD and president of Insulin for Life USA and has advised numerous pharmaceutical and biotech companies. Melena Bellin, MD Professor, Division of Pediatric Endocrinology & Department of Surgery, University of Minnesota Dr. Bellin is a nationally recognized expert in islet cell transplantation for patients with type 1 diabetes and pancreatitis. As co-medical director of the Clinical Translational Research Services core at the University of Minnesota, she has helped lead multiple clinical studies and contributes extensively to translational research initiatives aimed at improving patient outcomes through cellular therapies. Andrew Posselt, MD, PhD Transplant and Bariatric Surgeon, Director, Pancreatic Islet Transplant Program, UCSF Medical Center Dr. Posselt is a surgeon-scientist with deep experience in transplant immunology and clinical islet cell transplantation. At UCSF, he performs kidney, liver, and pancreas transplants and leads clinical research in both islet transplantation and bariatric surgery. His work focuses on mechanisms of transplant tolerance and improving outcomes in metabolic diseases. Holger Russ, PhD Associate Professor, Department of Pharmacology and Therapeutics, University of Florida Dr. Russ leads a research program focused on regenerative medicine and the cellular mechanisms that drive autoimmune type 1 diabetes. His lab uses human pluripotent stem cell technology and genetic engineering to model disease and develop novel treatments. He is a leader in beta-cell biology, thymic immunology, and stem cell-based interventions. 'We are truly honored to welcome such a renowned group of clinical and scientific leaders that believe in our mission to provide our Cell Pouch Bio-hybrid Organ as a potential functional cure for persons living with T1D, and want to help us get there,' said Jonathan Rigby, CEO and President of Sernova. 'Their collective expertise in T1D care, islet transplantation, islet cell biology, immunology, and clinical trial execution is of great value to Sernova and the patients we serve.' ABOUT SERNOVA BIOTHERAPEUTICS Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders. FOR FURTHER INFORMATION, PLEASE CONTACT: David Burke VP, Investor Relations (917) 751-5713 Email: [email protected] Website: The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release. FORWARD-LOOKING INFORMATION This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release include our belief that our Cell Pouch Bio-hybrid Organ could become a functional cure for T1D. With respect to the forward-looking statements contained in this press release, Sernova has made numerous assumptions regarding, among other things: the company's ability to secure additional financing on reasonable terms, or at all; and the ability to conduct all required preclinical and clinical studies for the company's Cell Pouch, including the timing and results of those trials. A more complete discussion of the risks and uncertainties facing Sernova appears in Sernova's Annual Information Form for the year ended October 31, 2024, filed with Canadian securities authorities and available at as updated by Sernova's continuous disclosure filings, which are available at All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Sernova disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Yahoo
22-05-2025
- Business
- Yahoo
Plant Stem Cell Market Review 2020-2024 and Forecast 2025-2030: Unilever, Renature Skin Care, and Other Key Players Leading the Industry
Key market opportunities in the Plant Stem Cell Market include leveraging the consumer shift toward natural and sustainable products, especially in cosmetics and healthcare, driving demand with biotechnological advancements, and capitalizing on regenerative medicine investments and eco-conscious trends for sustainable competitive advantages. Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Plant Stem Cell Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to Plant Stem Cell Market was valued at USD 401.02 Million in 2024 and is projected to reach USD 635.54 Million by 2030, rising at a CAGR of 8.12%. This market lies at the crossroads of biotechnology, healthcare, agriculture, and cosmetics, focusing on the use of stem cells derived from plants in applications ranging from skincare and nutraceuticals to pharmaceuticals and crop enhancement. Driven by the rising consumer preference for plant-based and sustainable products, coupled with significant biotechnological advancements, the industry is witnessing consistent growth. The expanding elderly population and growing awareness of anti-aging and regenerative solutions have particularly fueled demand in cosmetic and healthcare sectors. Furthermore, increasing investment in regenerative medicine, as seen in strategic collaborations such as the Wipro and Pandorum Technologies partnership in 2022, continues to spur innovation and expand the market's potential across multiple verticals. Key Market Driver: Rising Demand for Natural and Organic ProductsThe increasing global preference for natural and organic ingredients has emerged as a critical driver of growth in the Plant Stem Cell Market. Consumers are becoming more health-conscious and environmentally aware, leading them to favor products with plant-based origins over synthetic alternatives. In the skincare and personal care industry, plant stem cells are valued for their antioxidant and rejuvenating properties, offering benefits such as anti-aging effects and skin repair. This consumer shift is especially significant in cosmetics and dermatology, where the appeal of chemical-free, safe, and effective formulations continues to boost demand. Additionally, the perception of plant-derived products as sustainable and ethically produced further strengthens their adoption across sectors like nutraceuticals and healthcare, thereby fostering market Market Challenge: Regulatory Hurdles and Compliance IssuesNavigating the regulatory framework surrounding plant stem cell products presents a considerable challenge for market players. The absence of globally harmonized regulations leads to discrepancies in product approval procedures, labeling requirements, and classification standards across regions. This lack of standardization complicates product commercialization and increases compliance burdens, particularly for companies operating internationally. Additionally, concerns related to ethical sourcing, especially when rare or endangered plant species are used, pose further complications. Ensuring biodiversity conservation while maintaining a sustainable and scalable supply chain adds complexity to product development, affecting timelines and operational Market Trend: Growing Focus on Sustainable and Ethical SourcingSustainability and ethical sourcing are becoming central to product development in the Plant Stem Cell Market. Manufacturers are prioritizing environmentally responsible extraction methods and sustainable cultivation practices to meet regulatory expectations and consumer demand for clean-label ingredients. There is also a trend toward utilizing renewable plant sources and ensuring traceability in the supply chain. With the increasing influence of eco-conscious consumers, companies that commit to transparency and sustainable innovation are likely to gain competitive advantages. Moreover, product certifications and green marketing are playing a key role in shaping purchase decisions, especially in the cosmetics and healthcare Players Profiled in this Plant Stem Cell Market Report Uniliver PLC Renature Skin Care Inc. PhytoScience Ltd. Oriflame Cosmetics AG MyChelle Dermaceuticals LLC Mibelle Group AG Juice Beauty LLC Emsland Group GmbH Bio-FD&C Co., Ltd. Aidan Products LLC Report Scope Plant Stem Cell Market, by Location: Shoot Apical Meristems Root Apical Meristems Vascular Meristems Plant Stem Cell Market, by Application: Nutrition Pharmaceutical Cosmetics Plant Stem Cell Market, by Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE Key Attributes Report Attribute Details No. of Pages 190 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $401.02 Million Forecasted Market Value (USD) by 2030 $635.54 Million Compound Annual Growth Rate 8.1% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
